Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma

  • STATUS
    Recruiting
  • End date
    Jan 27, 2023
  • participants needed
    28
  • sponsor
    University of Wisconsin, Madison
Updated on 27 January 2022
carcinoma
metastasis
primary tumor

Summary

The specific aims of this study are:

  1. To determine the safety and feasibility of treating patients with a combination of MRI guided stereotactic body radiation therapy and microwave ablation.
  2. To assess short and long-term toxicity rates of patients treated with a combined modality approach.
  3. To assess local control, survival, and pathologic response to treatment

Description

Renal cell carcinoma is traditionally managed via a surgical approach. Increasingly, local therapy with radiofrequency and microwave ablation is being utilized as an alternative for patients who may not tolerate a nephrectomy or who refuse one. Although local control rates for small lesions are excellent, they drop off precipitously for lesions over 4 cm. Furthermore, lesions in critical areas such as the renal hilum may be difficult to treat with this method. Stereotactic body radiation therapy (SBRT) has had a long record of treating patients with inoperable tumors in locations such as the lung and central nervous system, and there is increasing evidence that it may be useful for patients with renal cell carcinoma. The recent emergence of MRI-guided radiation therapy allows for direct visualization of tumors during treatment, and may potentially allow clinicians to treat tumors more precisely. This phase I study will treat renal cell carcinoma patients using a combination of MRI-guided stereotactic body radiation therapy and microwave ablation.

Details
Condition Carcinoma, Renal Cell
Treatment Stereotactic Body Radiation Therapy (SBRT), Microwave Ablation (MWA)
Clinical Study IdentifierNCT02782715
SponsorUniversity of Wisconsin, Madison
Last Modified on27 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with imaging findings consistent with renal cell carcinoma
Deemed medically inoperable per urology evaluation
Tumor size >4cm in largest dimension
ECOG performance status of <2
Signed informed consent document(s)
Patients with metastatic disease will not be excluded

Exclusion Criteria

Patients who fail MRI screening
Pregnant or nursing women
History of prior radiation therapy to the upper abdomen
History of invasive cancer in the last 3 years (except for appropriately treated low-rist prostate cancer, treated non-melanoma/melanoma skin cancer, appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of breast and appropriately treated in-situ/early stage cervical/endometrial cancer)
Treatment with a non-approved or investigational drug within 28 days of study treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note